ArticlePloS one2010
ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 221 citations in OpenAlex.
- Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Trial
- Article
- Plasma proteomics of cerebrovascular disease, cognitive decline, and clinical outcomes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- A hepatocyte-derived GPNMB-RYK signaling axis in MASH progression.JHEP reports : innovation in hepatology · 2026Article
- A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer.Cancer discovery · 2026Article
- CaMKIIα inhibition facilitates functional recovery after preterm hypoxic-ischemic brain injury by disrupting microglial GPNMB signaling.Translational pediatrics · 2026Article
- GPNMB modulates neutrophil extracellular trap formation: therapeutic implications for ischemic stroke.Journal of neuroinflammation · 2026Article
- Trem2 exacerbates ischemic brain injury through Gpnmb in a photothrombotic stroke model.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The loss of glycoprotein nonmetastatic melanoma protein B (GPNMB) alters endothelial cell permeability, metabolism, and survival during infectious challenge.Clinical science (London, England : 1979) · 2026Article
- Spatial-reprogramming derived GPNMBGenome medicine · 2025Article
- Glycoprotein non-metastatic melanoma protein B is a potential biomarker for arthroplasty aseptic loosening.Scientific reports · 2025Article
- Single-cell spatial transcriptomics unravels the cellular landscape of abdominal aortic aneurysm.JCI insight · 2025Article
- Glycoprotein NMB mediates bidirectional GSC-TAM interactions to promote tumor progression.JCI insight · 2025Article
- Increased plasma GPNMB levels in patients with parkinson's disease and cognitive impairment.Scientific reports · 2025Article
- Temporal single-cell sequencing analysis reveals that GPNMB-expressing macrophages potentiate muscle regeneration.Experimental & molecular medicine · 2025Article
- Characterization of extracellular vesicle-associated DNA and proteins derived from organotropic metastatic breast cancer cells.Journal of experimental & clinical cancer research : CR · 2025Article
- GPNMB disrupts SNARE complex assembly to maintain bacterial proliferation within macrophages.Cellular & molecular immunology · 2025Article
- Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB.Journal of translational medicine · 2025Article
- Acquired resistance to immune checkpoint therapy is caused by glycoprotein non-metastatic melanoma protein B signal cascade.Communications medicine · 2025Article
- Identification of GPNMB in endometrial cancer based on pan-cancer analysis and in vitro validation.Discover oncology · 2024Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundGlycoprotein non-metastatic melanoma protein B (GPNMB)/Osteoactivin (OA) is a transmembrane protein expressed in approximately 40-75% of breast cancers. GPNMB/OA promotes the migration, invasion and metastasis of breast cancer cells; it is commonly expressed in basal/triple-negative breast tumors and is associated with shorter recurrence-free and overall survival times in patients with breast cancer. Thus, GPNMB/OA represents an attractive target for therapeutic intervention in breast cancer; however, little is known about the functions of GPNMB/OA within the primary tumor microenvironment. METHODOLOGY/PRINCIPAL
findingsWe have employed mouse and human breast cancer cells to investigate the effects of GPNMB/OA on tumor growth and angiogenesis. GPNMB/OA-expressing tumors display elevated endothelial recruitment and reduced apoptosis when compared to vector control-derived tumors. Primary human breast cancers characterized by high vascular density also display elevated levels of GPNMB/OA when compared to those with low vascular density. Using immunoblot and ELISA assays, we demonstrate the GPNMB/OA ectodomain is shed from the surface of breast cancer cells. Transient siRNA-mediated knockdown studies of known sheddases identified ADAM10 as the protease responsible for GPNMB/OA processing. Finally, we demonstrate that the shed extracellular domain (ECD) of GPNMB/OA can promote endothelial migration in vitro. CONCLUSIONS/SIGNIFICANCE: GPNMB/OA expression promotes tumor growth, which is associated with enhanced endothelial recruitment. We identify ADAM10 as a sheddase capable of releasing the GPNMB/OA ectodomain from the surface of breast cancer cells, which induces endothelial cell migration. Thus, ectodomain shedding may serve as a novel mechanism by which GPNMB/OA promotes angiogenesis in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.